Origin Sciences Appoints Paul Weinberger as CEO

Press Release: Origin Sciences Appoints Paul Weinberger as CEO

14 October 2015 — London and Cambridge, UK —

Origin Sciences Ltd, a medical technology company developing unique sampling devices and diagnostics for the stratification of patients with gastrointestinal diseases, has appointed Paul Weinberger as a company director and Chief Executive.

Paul joins Origin as the company prepares to develop and launch a series of new products using its novel sampling technology. Paul brings crucial sector expertise and commercial experience from a number of high level roles at companies including Lumora, Enigma Diagnostics and Roche Diagnostics. He remains as founder and Chief Executive of Diasolve, a company developing innovative medical technology for use in the cath lab, and serves as a member of both the NICE Diagnostics Advisory Committee and the board of BIVDA.

Commenting on his appointment, Paul Weinberger, said: “Origin is in an excellent position. Having developed some very strong sampling technology, it launched its first commercial product last year, and is now expanding its international sales and marketing presence. I am delighted to be joining at this critical time as the company moves to commercialise its products globally, and build on their unique capabilities to enable microbiome analysis and precision medicine for patients with gastrointestinal disease.”

Since 2014 Origin has made significant progress in developing and commercialising its diagnostic technology. Last year saw the launch of Oricol, a sampling device for investigating gastrointestinal disease, while 2015 has seen the company expand its commercial presence to South East Asia. In addition, the company has been active in expanding its scientific research and was able to publish data showing the benefits of using Oricol compared to traditional methods for research into gastrointestinal disease.